Claims for Patent: 5,972,919

Summary for Patent: 5,972,919

Title:	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
Abstract:	Effective amounts of formoterol (and/or a physiologically acceptable salt and/or solvate thereof) and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorder.
Inventor(s):	Carling; Christer Carl Gustav (Dalby, SE), Trofast; Jan William (Lund, SE)
Assignee:	Astra Aktiebolag (Sodertalje, SE)
Application Number:	08/944,683
Patent Claims:	1. A medicament containing as active ingredients effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1:70. 2. A pharmaceutical composition which comprises effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1:70, together with a pharmaceutically acceptable carrier. 3. A method for the treatment of asthma and other inflammatory respiratory disorders which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:4 to 1.70. 4. The method according to claim 3, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 .mu.g per day, and the effective amount of budesonide is 50-4800 .mu.g per day. 5. The method according to claim 4 wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-48 .mu.g per day, and the effective amount of budesonide is 100-1600 .mu.g per day. 6. The medicament of claim 1 wherein the active ingredients are in dry powder form. 7. The medicament of claim 1 or 6 wherein the formoterol is in the form of the fumarate dihydrate. 8. The pharmaceutical composition of claim 2 wherein the formoterol is in the form of the fumarate dihydrate. 9. The method according to any one of claims 3-5 wherein the administration is performed from a dry powder inhaler. 10. The method according to claim 9 wherein the inhaler is a Turbuhaler.RTM.. 11. The method according to any one of claims 3-5 wherein the administration is performed from a metered dose inhaler. 12. The method according to any one of claims 3-5 wherein the formoterol is in the form of the fumarate dihydrate. 13. A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable carrier is lactose. 14. A pharmaceutical composition according to claim 13 in dosage unit form. 15. The method according to any one of claims 3-5 wherein the administration is performed with a nebulizer. 16. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered simultaneously. 17. The method according to any one of claims 3-5 wherein the formoterol component is administered in admixture with the budesonide component. 18. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered sequentially. 19. The method according to any one of claims 3-5 wherein the formoterol component and the budesonide component are administered separately.